IDH1 wildtype gliomas represent hypo-methylation and elevate the expression of the PD-L1 gene [34], the TCGA dataset showed that AP-2αlow/PD-L1high was associated with wild-type IDH1 and glioma subtypes (classical, mesenchymal, neural), indicating the potential clinical significance of AP-2α in molecular classification and IDH1-wildtype glioma immunotherapy. Here, IDH1 is linked to central nervous system cancer.